Gene Kim, MD
Glaucoma Specialist · Bronx, NYNPI 1033474820
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Glaukos Corporation at 26.0% of the total. Reporting peaked in 2024 at $1,231 and has fallen 88.7% since, to $139 in 2025.
Across 36 payments — averaging $110.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$1K
- Alcon$748
- Aerie Pharmaceuticals, Inc.$581
- Sight Sciences, Inc.$477
- Bausch & Lomb Americas Inc.$361
- Carl Zeiss Meditec USA, Inc.$243
- plus $536 from 5 others
Across 1 payment — averaging $804.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$804
What the payments were for
- Food & beverage$3,983100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 7 | $1,037 |
| Alcon | 9 | $748 |
| Aerie Pharmaceuticals, Inc. | 5 | $581 |
| Sight Sciences, Inc. | 6 | $477 |
| Bausch & Lomb Americas Inc. | 3 | $361 |
| Carl Zeiss Meditec USA, Inc. | 1 | $243 |
| NEW World Medical,inc. | 1 | $242 |
| Ivantis, Inc | 1 | $133 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $124 |
| Abbott | 1 | $24 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$505
- iStent inject W$467
- Tecnis IOL$371
- enVista MX60 IOL$361
- Rocklatan$361
- Hydrus Microstent$283
- iStent inject Trabecular Micro-Bypass Stent System$270
- KXL System$261
- Photrexa$261
- OMNI(R) SURGICAL SYSTEM (US)$255
- Kahook Dual Blade$242
- Streamline Surgical System$242
- Ahmed Glaucoma Valve$242
- IACCESS$206
- iDose$158
- Clareon$153
- Tecnis Simplicity$124
- AcrySof IQ VIVITY IOL$108
How this compares
$3,983 in reported general payments places this provider in the 65th percentile of 35 glaucoma specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 388 | $393,248 |
| LumiganBimatoprost | 153 | $95,727 |
| CombiganBrimonidine Tartrate/Timolol | 166 | $64,969 |
| XiidraLifitegrast | 67 | $52,319 |
| RhopressaNetarsudil Mesylate | 130 | $47,734 |
| Prednisolone Acetate | 759 | $44,317 |
| Cyclosporine | 69 | $27,761 |
| Latanoprost | 3,204 | $24,847 |
| Brimonidine Tartrate | 1,086 | $15,688 |
| VyzultaLatanoprostene Bunod | 57 | $14,316 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 883 | $13,032 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 48 | $12,228 |
| RocklatanNetarsudil Mesylat/Latanoprost | 35 | $11,676 |
| Brinzolamide | 75 | $10,592 |
| Ketorolac Tromethamine | 598 | $8,957 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $13 | $557,926719 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $361 | $66,635124 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $581 | $59,410165 claims |
| AlconSimbrinza | $748 | $12,22848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 glaucoma specialist providers in New York.
Other glaucoma specialist in Bronx
- Brian KrawitzBronx$4K
- Jeffrey SchultzBronx$2K
- Janet SerleNew York$103K
- Sarah VantasselNew York$76K
- Jonathan SchulhofBrooklyn$73K
- Sonya DharNew York$19K
- Jacqueline LenociCommack$13K
- Tak Yee Tania TaiBrooklyn$11K
- Leah UmfreyAlbany$6K
- Smitha VoletiYonkers$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.